scholarly journals The Potential of Stem Cell Therapy to Repair White Matter Injury in Preterm Infants: Lessons Learned From Experimental Models

2019 ◽  
Vol 10 ◽  
Author(s):  
Josine E. G. Vaes ◽  
Marit A. Vink ◽  
Caroline G. M. de Theije ◽  
Freek E. Hoebeek ◽  
Manon J. N. L. Benders ◽  
...  
2021 ◽  
Vol 19 ◽  
Author(s):  
Aditya A Singh ◽  
Akash Kharwar ◽  
Manoj P. Dandekar

Background: Stroke is a serious neurovascular problem and the leading cause of disability and death worldwide. The disrupted demand to supply ratio of blood and glucose during cerebral ischemia develops hypoxic shock, and subsequently necrotic neuronal death in the affected regions. Multiple causal factors like age, sex, race, genetics, diet, and lifestyle play an important role in the occurrence as well as progression of post-stroke deleterious events. These biological and environmental factors may be contributed to vasculature variable architecture and abnormal neuronal activity. Since recombinant tissue plasminogen activator is the only clinically effective clot bursting drug, there is a huge unmet medical need for newer therapies for the treatment of stroke. Innumerous therapeutic interventions have shown promise in the experimental models of stroke but failed to translate it into clinical counterparts. Methods: Original publications regarding pathophysiology, preclinical experimental models, new targets and therapies targeting ischemic stroke have been reviewed since the 1970s. Results: We highlighted the critical underlying pathophysiological mechanisms of cerebral stroke and preclinical stroke models. We discuss the strengths and caveats of widely used ischemic stroke models, and commented on the potential translational problems. We also describe the new emerging treatment strategies, including stem cell therapy, neurotrophic factors and gut microbiome-based therapy for the management of post-stroke consequences. Results : We highlighted the critical underlying pathophysiological mechanisms of cerebral stroke and preclinical stroke models. We discuss the strengths and caveats of widely used ischemic stroke models, and commented on the potential translational problems. We also describe the new emerging treatment strategies, including stem cell therapy, neurotrophic factors and gut microbiome-based therapy for the management of post-stroke consequences. Conclusion: There are still many inter-linked pathophysiological alterations with regards to stroke, animal models need not necessarily mimic the same conditions of stroke pathology and newer targets and therapies are the need of the hour in stroke research.


2021 ◽  
Vol 12 ◽  
Author(s):  
Nadia Sadanandan ◽  
Madeline Saft ◽  
Bella Gonzales-Portillo ◽  
Cesar V. Borlongan

Epilepsy stands as a life-threatening disease that is characterized by unprovoked seizures. However, an important characteristic of epilepsy that needs to be examined is the neuropsychiatric aspect. Epileptic patients endure aggression, depression, and other psychiatric illnesses. Therapies for epilepsy can be divided into two categories: antiepileptic medications and surgical resection. Antiepileptic drugs are used to attenuate heightened neuronal firing and to lessen seizure frequency. Alternatively, surgery can also be conducted to physically cut out the area of the brain that is assumed to be the root cause for the anomalous firing that triggers seizures. While both treatments serve as viable approaches that aim to regulate seizures and ameliorate the neurological detriments spurred by epilepsy, they do not serve to directly counteract epilepsy’s neuropsychiatric traits. To address this concern, a potential new treatment involves the use of stem cells. Stem cell therapy has been employed in experimental models of neurological maladies, such as Parkinson’s disease, and neuropsychiatric illnesses like depression. Cell-based treatments for epilepsy utilizing stem cells such as neural stem cells (NSCs), mesenchymal stem cells (MSCs), and interneuron grafts have been explored in preclinical and clinical settings, highlighting both the acute and chronic stages of epilepsy. However, it is difficult to create an animal model to capitalize on all the components of epilepsy due to the challenges in delineating the neuropsychiatric aspect. Therefore, further preclinical investigation into the safety and efficacy of stem cell therapy in addressing both the neurological and the neuropsychiatric components of epilepsy is warranted in order to optimize cell dosage, delivery, and timing of cell transplantation.


2017 ◽  
Vol 2 (1) ◽  
Author(s):  
Sushmitha Durgam ◽  
Matthew Stewart

<p>This Knowledge Summary addresses the published information supporting intralesional administration of cell-based therapies for the treatment of flexor tendinitis/tendinopathy in horses. The current body of evidence supports intralesional stem cell therapy to improve quality of repair tissue during equine SDFT healing, based on histological and histomorphometric analyses and, in some studies, tensile load testing. Accepting this, comparative analyses to determine relative efficacies of specific cell sources are inadequate to draw any firm conclusions on this issue and any informative meta-analysis of the existing studies is confounded by inconsistencies in cell sources, injury models and clinical case selections, times after injury when cells were injected, number of cells administered, delivery vehicles used, the outcomes used to assess utility and timing of outcomes after administration. Further, in none of the experimental studies were the horses subject to training and/or racing stresses, and it is still unclear how closely the existing experimental models reflect the clinical condition following repetitive strain injury. Further, single-cycle tensile testing does not necessarily model the high-frequency, recurrent, and (to be hoped) submaximal tensile loading that flexor tendons experience during high speed exercise.</p><p> </p><img src="https://www.veterinaryevidence.org/rcvskmod/icons/oa-icon.jpg" alt="Open Access" /> <img src="https://www.veterinaryevidence.org/rcvskmod/icons/pr-icon.jpg" alt="Peer Reviewed" />


2016 ◽  
Vol 39 (4) ◽  
pp. 513-518 ◽  
Author(s):  
Stephanie Dooves ◽  
Marjo S. van der Knaap ◽  
Vivi M. Heine

Sign in / Sign up

Export Citation Format

Share Document